LKT Labs

Biochemicals for Life Science Research

Acalabrutinib

Product ID A081014
Cas No. 1420477-60-6
Purity ≥99%
Product Unit SizeCostQuantityStock
5 mg $85.00 Please Inquire
25 mg $225.00 Please Inquire
100 mg $650.00 Please Inquire
Bulk Quote
Browse Wishlist

Quicklinks

Description

Acalabrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK). It showed increased selectivity compared with first generation BTK inhibitors such as ibrutinib while offering similar antitumor efficacy in mouse models of chronic lymphocytic leukemia. It has been approved for the treatment of patients with relapsed mantle cell lymphoma(MCL), a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. It is currently being investigated as a front line treatment for MCL.

Product Info

Cas No.

1420477-60-6
Purity

≥99%
Formula

C26H23N7O2
Formula Wt.

465.52
IUPAC Name

4-{8-Amino-3-[(2S)-1-(2-butynoyl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl}-N-(2-pyridinyl)benzamide
Synonym

ACP-196

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

A081014 MSDS PDF
Info Sheet

A081014 Info Sheet PDF

References

Herman S., Montraveta A., et al. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. Clin Cancer Res. 23(11):2831-41 (2016). PMID:27903679.

Witzig T., Inwards D. Acalabrutinib for mantle cell lymphoma. Blood. 133(24):2570-74 (2019). PMID: 30967367.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.